The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

(2015) Takahisa Kawamura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

(2015) M.J. Ahn et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations

(2015) Lei Gong et al.   LUNG CANCER

Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials

(2015) M. Burotto et al.   ONCOLOGIST

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells

(2015) Shigeki Nanjo et al.   Oncotarget

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

(2015) David M. Jackman et al.   Oncotarget

Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors

(2014) Jeanny Kwon et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis

(2014) Chou-Han Lin et al.   LUNG CANCER

Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure

(2014) Haihong Yang et al.   Targeted Oncology

Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

(2013) Wei-Xiang Qi et al.   Asian Pacific Journal of Cancer Prevention

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

(2013) S. Alimujiang et al.   Asian Pacific Journal of Cancer Prevention

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

(2013) Eunyoung Lee et al.   Journal of Thoracic Oncology

High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—One with a remarkable thoracic response as well

(2013) J.L. Kuiper et al.   LUNG CANCER

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

(2012) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature

(2012) Yosuke Togashi et al.   LUNG CANCER

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group

(2012) Shigeki Umemura et al.   LUNG CANCER

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

(2012) Ying Yuan et al.   World Journal of Surgical Oncology

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

(2011) Takeshi Masuda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

(2011) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer

(2011) Akito Hata et al.   Journal of Thoracic Oncology

Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy

(2011) Patrick G. Morris et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection

(2011) Akito Hata et al.   LUNG CANCER

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era

(2011) Jin Hyun Park et al.   LUNG CANCER

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

(2011) C. Grommes et al.   NEURO-ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

(2010) S. Heon et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

(2010) Geoffrey R. Oxnard et al.   CLINICAL CANCER RESEARCH

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis

(2010) Karin Oechsle et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

(2010) Jennifer L. Clarke et al.   JOURNAL OF NEURO-ONCOLOGY

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations

(2010) Jenn-Yu Wu et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carcinomatous Meningitis in Non–Small-Cell Lung Cancer: Response to High-Dose Erlotinib

(2009) Nirav Dhruva et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib

(2009) Tatsuya Katayama et al.   Journal of Thoracic Oncology

EGFR testing in lung cancer is ready for prime time

(2009) Fred R Hirsch et al.   LANCET ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

(2009) Kyoichi Kaira et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

(2009) Hua-Jun Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

(2008) Hyeon Gyu Yi et al.   LUNG CANCER